[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644210":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":59,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":26,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":26,"overallStatus":81,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Esketamine Group","EXPERIMENTAL","Participants in this arm will receive an intravenous bolus of esketamine 0.3 mg\u002Fkg (administered over 1 minute) after anesthesia induction, followed by a continuous infusion of 0.3 mg\u002Fkg\u002Fh, which will be discontinued 30 minutes before the end of surgery. The drug will be prepared in normal saline to a total volume of 10 mL and administered in a double-blind manner",[13],"Drug: esketamine",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal Saline Group","PLACEBO_COMPARATOR","Participants in this arm will receive an equal volume of normal saline at the same time points as the experimental group: a bolus after anesthesia induction followed by a continuous infusion, which will be discontinued 30 minutes before the end of surgery. The placebo will be prepared in identical syringes to maintain blinding",[19],"Drug: Normal Saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","esketamine","Esketamine is administered as an intravenous bolus of 0.3 mg\u002Fkg (over 1 minute) after anesthesia induction, followed by a continuous intravenous infusion of 0.3 mg\u002Fkg\u002Fh until 30 minutes before the end of surgery. The drug is diluted with normal saline to a total volume of 10 mL and prepared in identical syringes to ensure blinding. This intervention is used as the experimental treatment to assess its effect on postoperative cognitive recovery in elderly patients undergoing oral and maxillofacial surgery",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal Saline","Normal saline is used as the placebo control. It is administered as an intravenous bolus of equal volume after anesthesia induction, followed by a continuous intravenous infusion at an equal rate until 30 minutes before the end of surgery. The saline is prepared in identical syringes to the experimental drug to maintain double-blind conditions. This intervention serves as the comparator to evaluate the specific effect of esketamine on postoperative cognitive recovery",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Haopeng Zhang","CONTACT","+86 17791305967","haopeng.zhang@foxmail.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Guanghui Hao","+8615291285018","15291285018@163.com",[42],{"facility":43,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The Third Affiliated Hospital of Air Force Medical University","Xi'an","Shaanxi","710032","China","CN",{"type":50,"coordinates":51},"Point",[52,53],108.92861,34.25833,{"lat":53,"lon":52},[56],{"name":57,"role":34,"phone":58,"phoneExt":26,"email":40},"Guanghui Hao, Master's Candidate","+86 15291285018",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Zhang Haopeng","Chief Physician","100644210","the-effect-of-esketamine-on-postoperative-cognitive-function-in-elderly-patients-undergoing-oral-and-maxillofacial-surgery-100644210",false,"NCT07665099","The Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery","Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery: A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial","Inclusion Criteria:\n\nAge ≥ 60 years, either sex; Scheduled for elective oral and maxillofacial surgery under general anesthesia (including oral and maxillofacial tumor surgery, orthognathic surgery, and maxillofacial trauma repair surgery); American Society of Anesthesiologists (ASA) physical status I-III; Expected duration of anesthesia ≥ 2 hours; Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\nPre-existing behavioral disorders or psychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease), or current use of antipsychotic medications (e.g., clozapine, risperidone, olanzapine, haloperidol, chlorpromazine); Pre-existing severe organ dysfunction including: severe cardiovascular disease (life-threatening arrhythmias, severe uncontrolled hypertension, coronary artery disease, heart failure), severe respiratory disease (respiratory failure, severe chronic obstructive pulmonary disease), severe hepatic insufficiency (Child-Pugh Class C), or severe renal insufficiency (glomerular filtration rate \\\u003C 30 mL\u002Fmin or creatinine \\> 2.5 mg\u002FdL); Known contraindications to esketamine including: hypersensitivity to the active substance or any excipients; severe risk of elevated blood pressure or intracranial pressure; uncontrolled or untreated hypertension (resting systolic\u002Fdiastolic blood pressure \\> 180\u002F100 mmHg); preeclampsia or eclampsia; untreated or inadequately treated hyperthyroidism; conditions requiring uterine relaxation (e.g., uterine rupture, umbilical cord prolapse); use as the sole anesthetic in patients with significant ischemic heart disease; Surgical approach that would interfere with postoperative MoCA assessment; Concurrent participation in another clinical trial; Pre-existing cognitive impairment or Mini-Mental State Examination (MMSE) score \\\u003C 24, unable to complete questionnaire-based assessments.","ALL","60 Years",{"count":73,"type":74},98,"ESTIMATED","INTERVENTIONAL",[77],"NA","Esketamine is a common anesthetic adjuvant. Previous studies have shown that it may have protective effects on the brain. This study aims to investigate whether esketamine can improve cognitive function recovery in elderly patients (aged 60 years and older) undergoing oral and maxillofacial surgery.\n\nParticipants will be randomly assigned to receive either esketamine or a placebo (normal saline) during anesthesia. Neither the participants nor the researchers will know which treatment is given.\n\nCognitive function will be assessed using standardized tests before surgery and at 1, 3, 7, and 15 days after surgery. Sleep quality, pain scores, emotional status, and adverse events will also be recorded. Blood samples will be collected to explore potential mechanisms.\n\nThe study is expected to enroll approximately 98 participants at the Third Affiliated Hospital of Air Force Medical University in Xi'an, China. Participation will last about 16 days from the day before surgery to the final follow-up on day 15 after surgery.",[80],"Perioperative Neurocognitive Disorders","NOT_YET_RECRUITING","2026-06-18",{"date":84,"type":85},"2026-06-24","ACTUAL",{"date":87,"type":74},"2026-07-01",{"date":89,"type":74},"2027-01-31",{"name":5,"class":6},1]